Androgen-independent effects of serenoa repens extract (Prostasan ®) on prostatic epithelial cell proliferation and inflammation

Phytotherapy Research

Volumn 26, Issue 2, 2012, Pages 259-264

  Iglesias Gato, Diego ^a   Carsten, Tober ^b   Vesterlund, Mattias ^a   Pousette, Ake ^a   Schoop, Roland ^c   Norstedt, Gunnar ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Rent a lab   (Germany)

^c A Vogel Bioforce AG   (Switzerland)

Author keywords

BPH; inflammation; PC 3 cell line; proliferation; prostatitis; Serenoa repens

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTASAN; SABAL EXTRACT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; HORMONE ACTION; MITOSIS INHIBITION; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

SERENOA REPENS;

EID: 84856270111     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3537     Document Type: Article

References (32)

1. Bayne CW, Donnelly F, Ross M, Habib FK,. 1999. Serenoa repens (Permixon): a 5-alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. The Prostate 40: 232-241. (Pubitemid 29398049)
2. Bonvissuto G, Minutoli L, Morgia G, et al,. 2011. Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study. Urology 77 (1): 248.e9-16.
3. De Marzo AM, Marchi VL, Epstein JI, Nelson WG,. 1999. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155: 1985-1992.
4. Délos S, Iehlé C, Martin PM, Raynaud JP,. 1994. Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 48: 347-352. (Pubitemid 24128599)
5. Di J-m, Pang J, Pu X-y, et al,. 2009. Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells. Cancer Genet Cytogenet 192: 60-67.
6. Di Silverio F, Monti S, Sciarra A, et al,. 1998. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37: 77-83. (Pubitemid 28440133)
7. Di Silverio F, Gentile V, De Matteis, A, et al,. 2003. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43: 164-175. (Pubitemid 36221971)
8. Fagelman E, Lowe FC,. 2001. Saw palmetto berry as a treatment for BPH. Rev Urol 3: 134-138.
9. Festuccia C, Angelucci A, Gravina GL, et al,. 2005. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 93: 964-975. (Pubitemid 40691556)
10. Fujita K, Ewing CM, Getzenberg RH, et al,. 2010. Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate 70: 473-481.
11. Habib FK, Ross M, Ho CKH, et al,. 2005. Serenoa repens (Permixon) inhibits the 5-alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 114: 190-194. (Pubitemid 40194287)
12. Hill B, Kyprianou N,. 2004. Effect of permixon on human prostate cell growth: lack of apoptotic action. The Prostate 61: 73-80. (Pubitemid 39095696)
13. Hong H, Kim C-S, Maeng S,. 2010. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract 3: 323-327.
14. Kaighn ME, Narayan KS, Ohnuki Y, et al,. 1979. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23. (Pubitemid 9239413)
15. Kundu SD, Lee C, Billips BK, et al,. 2008. The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 68: 223-229. (Pubitemid 351186234)
16. MacLaughlin BW, Gutsmuths B, Pretner E, et al,. 2006. Effects of homeopathic preparations on human prostate cancer growth in cellular and animal models. Integr Cancer Ther 5: 362-372. (Pubitemid 44721993)
17. Marengo SR, Chung LW,. 1994. An orthotopic model for the study of growth factors in the ventral prostate of the rat: effects of epidermal growth factor and basic fibroblast growth factor. J Androl 15: 277-286. (Pubitemid 24256640)
18. Pais P,. 2010. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II. Adv Ther 27: 555-556.
19. Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P,. 1997. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 57: 299-304. (Pubitemid 27454265)
20. Pei Z, Li H, Guo Y, et al,. 2009. Sodium selenite inhibits the expression of VEGF, TGFβ1 and IL-6 induced by LPS in human PC3 cells via TLR4-NF-KB signaling blockage. Internat Immunopharmacol 10: 50-56.
21. Penna G, Mondaini N, Amuchastegui S, et al,. 2007. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 51: 524-533; discussion 533. (Pubitemid 44937795)
22. Petrangeli E, Lenti L, Buchetti B, et al,. 2009. Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization. J Cell Physiol 219: 69-76.
23. Raynaud JP, Cousse H, Martin PM,. 2002. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J Steroid Biochem Mol Biol 82: 233-239. (Pubitemid 35435372)
24. Robert G, Descazeaud A, Nicolaîew N, et al,. 2009. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. The Prostate 69: 1774-1780.
25. Rodríguez-Berriguete G, Prieto A, Fraile B, et al,. 2010. Relationship between IL-6/ERK and NF-ΰB: a study in normal and pathological human prostate gland. Eur Cytokine Netw 21: 241-250.
26. Royuela M, Ricote M, Parsons MS, et al,. 2004. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 202: 41-49. (Pubitemid 38072844)
27. St Sauver JL, Jacobsen SJ,. 2008. Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms. Curr Prostate Rep 6: 67-73.
28. Suzuki M, Oki T, Sugiyama T, et al,. 2007. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 69: 1216-1220. (Pubitemid 46891580)
29. Tacklind J, MacDonald R, Rutks I, et al,. 2009. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev doi: 10.1002/14651858. CD001423.pub2.
30. Tan L, Xie Q, Jia, X, et al,. 2009. Dynamic measurement of the surface stress induced by the attachment and growth of cells on Au electrode with a quartz crystal microbalance. Biosens Bioelectron 24: 1603-1609.
31. Wilt T, Ishani A, Mac Donald R,. 2002. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev doi: 10.1002/14651858. CD001423.
32. Yang Y, Ikezoe T, Zheng Z, et al,. 2007. Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int J Oncol 31: 593-600.